Pharmacogenetics of Colorectal Cancer
Author Information
Author(s): Ana Comes-Raga, Luis Sendra Gisbert, Goitzane Marcaida-Benito, Salvador F. Aliño Pellicer, María José Herrero Cervera
Primary Institution: Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Hypothesis
The study aims to determine the frequency of genetic variants associated with adverse drug reactions and survival in colorectal cancer patients.
Conclusion
The study found that certain genetic variants were associated with lower survival rates in colorectal cancer patients.
Supporting Evidence
- 3.5% of patients had the rs75017182 mutation in the DPYD gene.
- 4.7% had the rs1801158 mutation in the DPYD gene.
- 7.1% had the rs1801160 mutation in the DPYD gene.
- 39.4% of patients had the *1/*1 genotype in the UGT1A1 gene.
- 37.9% had the *1/*28 genotype in the UGT1A1 gene.
- 19.7% had the *28/*28 genotype in the UGT1A1 gene.
- 42% of patients developed neurotoxicity.
- 68% of patients reported gastrointestinal reactions.
Takeaway
This study looked at how people's genes affect their response to cancer treatment, finding that some genetic changes can lead to worse outcomes.
Methodology
Genotyping of 25 SNPs was performed using MassArray technology, and correlations were assessed using logistic regression.
Limitations
The study results should be confirmed in a larger cohort with more powerful statistical analyses.
Participant Demographics
39% women, 56% men, ages 28 to 83, with a median age of 67 years.
Statistical Information
P-Value
0.006, <0.001, 0.052
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website